
Mandya to undergo changes after patient's death
Mandya: In response to growing concerns over basic facilities at the Mandya Institute of Medical Sciences (MIMS) — particularly following the death of a three-year-old girl at the hospital on May 27 — Mandya MLA P Ravikumar and deputy commissioner Kumara convened a high-level meeting with MIMS officials on Monday.
Tired of too many ads? go ad free now
Several key directives were issued to improve infrastructure, hygiene and service quality at the hospital. To ensure punctuality and transparency, biometric attendance software will be implemented for all staff.
Highlighting drinking water as a basic necessity, the MLA acknowledged complaints about a severe shortage of potable water for patients and the public. As an immediate remedy, he approved the installation of two Reverse Osmosis (RO) drinking water units using MLA development funds.
Officials have been instructed to identify and install these units in high-traffic areas within the hospital premises.
Addressing long-standing complaints about parking mismanagement, Ravikumar directed that CCTV cameras be installed in the parking area. He also emphasised the need for electronic ticketing systems to log vehicle entry and exit times. The traffic police have been instructed to conduct regular inspections, especially in light of reports that some vehicles remain parked for extended periods without oversight.
Expressing dissatisfaction with the current food services, the MLA proposed revamping the hospital canteen. He encouraged the involvement of women's self-help groups in establishing an 'Akka Canteen', which could receive financial assistance of up to Rs 5 lakh. Officials were urged to ensure the availability of clean, nutritious and affordable food for patients and visitors.
Deputy commissioner Kumara laid out hygiene protocols, including the mandatory cleaning of toilets three times daily, monitored via a logbook.
Tired of too many ads? go ad free now
He also mandated that all hospital equipment and items be labelled with "MIMS" to prevent misuse or misplacement. To improve patient experience, especially for vulnerable groups, separate queues are to be arranged in the Outpatient Department (OPD) and pharmacy for women and persons with disabilities.
Adequate staffing must be ensured to support these changes.
A new 100-bed facility at Arogya Dhaama was completed, and contract staff will be appointed to manage it.
The administration was also instructed to monitor complaints about doctors allegedly directing patients to purchase medicines from private pharmacies.
To maintain oversight and swiftly resolve emerging issues, it was recommended that senior hospital officials — including the director, medical superintendent, resident medical officer, and chief administrative officer — conduct daily inspections. The meeting was attended by MIMS director Dr Narasimha Swamy and other senior hospital officials, who assured full cooperation in implementing the directives.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
an hour ago
- Economic Times
Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatment
Dr Reddy's (File Photo) Dr Reddy's Laboratories on Thursday said it has joined hands with global biotech firm Alvotech to co-develop and commercialise a biosimilar product for treating multiple types of cancer. The Hyderabad-based drug major has entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets, Dr Reddy's Laboratories said in a statement. Keytruda (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were USD 29.5 billion. The collaboration combines Dr Reddy's and Alvotech's proven capabilities in biosimilars thereby speeding up the development process and extending the global reach for this biosimilar candidate, the company noted. Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, it stated. Subject to certain exceptions, each party will have the right to commercialize the product globally, it added. "Oncology has been a top focus therapy area for us and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology," Dr Reddy's CEO Erez Israeli said. Alvotech chairman and CEO Robert Wessman said the agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of its pipeline by pursuing growing global markets. "It further enables us to increase the availability of cost-effective, critical biologic medications to patients world-wide," he added. Dr Reddy's shares were trading 3.49 per cent up at Rs 1,295.80 apiece on BSE.


Time of India
an hour ago
- Time of India
Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatment
Dr Reddy's Laboratories on Thursday said it has joined hands with global biotech firm Alvotech to co-develop and commercialise a biosimilar product for treating multiple types of cancer. The Hyderabad-based drug major has entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets, Dr Reddy's Laboratories said in a statement. Keytruda (pembrolizumab) is indicated for the treatment of numerous cancer types. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Con la ayuda de la IA y los CFDs, una inversión puede convertirse en tu ingreso adicional. Trade AI Undo In 2024, worldwide sales of Keytruda were USD 29.5 billion. The collaboration combines Dr Reddy's and Alvotech's proven capabilities in biosimilars thereby speeding up the development process and extending the global reach for this biosimilar candidate, the company noted. Live Events Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, it stated. Subject to certain exceptions, each party will have the right to commercialize the product globally, it added. "Oncology has been a top focus therapy area for us and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology ," Dr Reddy's CEO Erez Israeli said. Alvotech chairman and CEO Robert Wessman said the agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of its pipeline by pursuing growing global markets. "It further enables us to increase the availability of cost-effective, critical biologic medications to patients world-wide," he added. Dr Reddy's shares were trading 3.49 per cent up at Rs 1,295.80 apiece on BSE .


India Today
an hour ago
- India Today
Dr Reddy's shares jump over 3% today. Here's why
Dr Reddy's Laboratories shares rose over 3% on Thursday, emerging as the top gainer on the Nifty Pharma index, which climbed 1.4%. Around 1:03 pm, the stock was up 3.39% at Rs 1, surge follows the announcement of a strategic partnership with US-listed biotech firm Alvotech to develop a biosimilar version of Merck's blockbuster cancer drug Keytruda (pembrolizumab). The PD-1 inhibitor, used to treat multiple cancer types, is expected to generate $29.5 billion in global sales in 2024, making it one of the most valuable targets in the biosimilars the agreement, Dr Reddy's and Alvotech will share development and manufacturing responsibilities and retain commercialisation rights globally, with a few Israeli, CEO of Dr Reddy's, called the deal a 'major step' in the company's oncology strategy. 'This collaboration enhances our capabilities in immuno-oncology and reinforces our focus on affordable, high-quality treatment options,' he which already markets biosimilars of Humira and Stelara, sees this partnership as a way to further leverage its R&D and manufacturing platform. 'This agreement demonstrates our ability to accelerate development of key biosimilars,' said chairman and CEO Rbert market has reacted positively to the development. While Dr Reddy's shares are down 5.3% on a year-to-date basis, they have gained 10.5% in the past month. Analysts see the move as a strategic bet to boost the company's global presence in the competitive biosimilar Direct described the Keytruda biosimilar as a 'decent pipeline opportunity' despite expected competition. At a forward 12-month PE of 18.8, Dr Reddy's remains the third-cheapest stock on the Nifty Pharma oncology being a core focus area and biosimilars gaining momentum globally, the collaboration with Alvotech marks a critical step in Dr Reddy's long-term growth The views, opinions, recommendations, and suggestions expressed by experts/brokerages in this article are their own and do not reflect the views of the India Today Group. It is advisable to consult a qualified broker or financial advisor before making any actual investment or trading choices.)Must Watch